HUTCHMED (China) Ltd (HCM): Total Liabilities
$501.83M
As of 2025-12-31
+8.5%
3-year compound annual growth
+19.6%
5-year compound annual growth
+14.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $501.83M | -0.1% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $502.34M | -6.3% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $536.39M | +36.6% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $392.57M | +17.8% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $333.15M | +62.4% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $205.17M | +34.8% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $152.22M | +27.0% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $119.86M | +6.1% | 2020-03-03, Balance as of period end |
| 2017-12-31 | $112.97M | -18.4% | 2019-03-11, Balance as of period end |
| 2016-12-31 | $138.38M | +8.7% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $127.32M | n/a | 2017-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗